abcam

Product datasheet

Alexa Fluor® 647 Anti-Tau antibody [SP70] ab279688

リコンピナント

画像数4

製品の概要

製品名 Alexa Fluor® 647 Anti-Tau antibody [SP70]

製品の詳細 Alexa Fluor® 647 Rabbit monoclonal [SP70] to Tau

由来種 Rabbit

Alexa Fluor® 647. Ex: 652nm, Em: 668nm

The specificity of this antibody refers to P10636-8.

アプリケーション 適用あり: IHC-P

適用なし: Flow Cyt (Intra) or ICC/IF

種交差性 交差種: Human

Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

IHC: human cerebrum, and breast cancer tissue

This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free production

For more information see here.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb[®] patents.

Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor[®] dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or

標識

特異性

免疫原

ポジティブ・コントロール

特記事項

outlicensing@thermofisher.com.

製品の特性

製品の状態 Liquid

保存方法 Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long

term. Avoid freeze / thaw cycle. Store In the Dark.

バッファー pH: 7.4

Preservative: 0.02% Sodium azide

Constituents: 30% Glycerol (glycerin, glycerine), 1% BSA, 68% PBS

精製度 Protein A purified

ポリ/モノ モノクローナル

クローン名 SP70 **Pイソタイプ I**gG

アプリケーション

The Abpromise guarantee

Abpromise保証は、次のテスト済みアプリケーションにおけるab279688の使用に適用されます

アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。

アプリケーション	Abreviews	特記事項
IHC-P		Use at an assay dependent concentration.

追加情報

Is unsuitable for Flow Cyt (Intra) or ICC/IF.

ターゲット情報

機能

Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.

組織特異性

 $\label{prop:pns} \text{Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the } \\$

others are expressed in the central nervous system.

関連疾患

Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).

Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.

Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.

Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.

Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

Contains 4 Tau/MAP repeats.

during mitosis.

Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.

The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.

Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, sevenfold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms

Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.

Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.

Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.

There are 9 isoforms produced by alternative splicing.

配列類似性

発生段階

ドメイン

翻訳後修飾

細胞内局在

製品の状態

画像




Immunohistochemistry (Formalin/PFA-fixed paraffinembedded sections) - Alexa Fluor® 647 Anti-Tau antibody [SP70] (ab279688)

skeletal muscle tissue labeling Tau with ab279688 at 1/50 (10.0 ug/ml) dilution followed by a ready to use . Negative control: no staining on human skeletal muscle. The section was then incubated overnight at +4°C in TBS containing 0.025% (v/v) Triton X-100 and 1% (w/v) BSA with ab279688 at 1/50 dilution (shown in red). Nuclear DNA was labeled with DAPI (shown in blue). The section was then mounted using Fluoromount.Non-specific protein-protein interactions were then blocked in TBS containing 0.025% (v/v) Triton X-100, 0.3M (w/v) glycine and 1% (w/v) BSA for 1h at room temperature.lmage was taken with a confocal microscope (Leica-Microsystems, TCS SP8). Counterstained with DAPI. Secondary antibody only control: Secondary antibody is a ready to

use.

Immunohistochemical analysis of paraffin-embedded Human

Heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0)




Immunohistochemistry (Formalin/PFA-fixed paraffinembedded sections) - Alexa Fluor® 647 Anti-Tau antibody [SP70] (ab279688)

Immunohistochemical analysis of paraffin-embedded Human cerebrum tissue labeling Tau with ab279688 at 1/50 (10.0 ug/ml) dilution followed by a ready to use . Positive staining on human cerebrum. The section was then incubated overnight at +4°C in TBS containing 0.025% (v/v) Triton X-100 and 1% (w/v) BSA with ab279688 at 1/50 dilution (shown in red). Nuclear DNA was labeled with DAPI (shown in blue). The section was then mounted using Fluoromount.Non-specific protein-protein interactions were then blocked in TBS containing 0.025% (v/v) Triton X-100, 0.3M (w/v) glycine and 1% (w/v) BSA for 1h at room temperature.lmage was taken with a confocal microscope (Leica-Microsystems, TCS SP8). Counterstained with DAPI.

Secondary antibody only control: Secondary antibody is a ready to

Heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0)




Immunohistochemistry (Formalin/PFA-fixed paraffinembedded sections) - Alexa Fluor® 647 Anti-Tau antibody [SP70] (ab279688)

Immunohistochemical analysis of paraffin-embedded Human breast cancer tissue labeling Tau with ab279688 at 1/50 (10.0 ug/ml) dilution followed by a ready to use . Positive staining on human breast cancer. The section was then incubated overnight at +4°C in TBS containing 0.025% (v/v) Triton X-100 and 1% (w/v) BSA with ab279688 at 1/50 dilution (shown in red). Nuclear DNA was labeled with DAPI (shown in blue). The section was then mounted using Fluoromount.Non-specific protein-protein interactions were then blocked in TBS containing 0.025% (v/v) Triton X-100, 0.3M (w/v) glycine and 1% (w/v) BSA for 1h at room temperature.Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8). Counterstained with DAPI.

Secondary antibody only control: Secondary antibody is a ready to use .

Heat mediated antigen retrieval using ${\color{red} \underline{ab93684}}$ (Tris/EDTA buffer, pH 9.0)



(ab279688)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- · Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- · Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit https://www.abcam.co.jp/abpromise or contact our technical team.

Terms and conditions

· Guarantee only valid for products bought direct from Abcam or one of our authorized distributors